Exploiting Tumor Epigenetics to Improve Oncolytic Virotherapy

Overview

Journal Front Genet

Date 2013 Sep 25

PMID 24062768

Citations 11

Authors

Nicole E Forbes

Hesham Abdelbary

Mathieu Lupien

John C Bell

Jean-Simon Diallo

Affiliations

Soon will be listed here.

Abstract

Oncolytic viruses (OVs) comprise a versatile and multi-mechanistic therapeutic platform in the growing arsenal of anticancer biologics. These replicating therapeutics find favorable conditions in the tumor niche, characterized among others by increased metabolism, reduced anti-tumor/antiviral immunity, and disorganized vasculature. Through a self-amplification that is dependent on multiple cancer-specific defects, these agents exhibit remarkable tumor selectivity. With several OVs completing or entering Phase III clinical evaluation, their therapeutic potential as well as the challenges ahead are increasingly clear. One key hurdle is tumor heterogeneity, which results in variations in the ability of tumors to support productive infection by OVs and to induce adaptive anti-tumor immunity. To this end, mounting evidence suggests tumor epigenetics may play a key role. This review will focus on the epigenetic landscape of tumors and how it relates to OV infection. Therapeutic strategies aiming to exploit the epigenetic identity of tumors in order to improve OV therapy are also discussed.

Citing Articles

The Advances in the Development of Epigenetic Modifications Therapeutic Drugs Delivery Systems.

Li T, Chen Y, Li S Int J Nanomedicine. 2024; 19:10623-10637.

PMID: 39445155 PMC: 11498046. DOI: 10.2147/IJN.S480095.

Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy.

Russo S, Feola S, Feodoroff M, Chiaro J, Antignani G, Fusciello M Mol Ther Oncol. 2024; 32(1):200766.

PMID: 38596301 PMC: 10869747. DOI: 10.1016/j.omton.2024.200766.

Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways.

Zhu Z, McGray A, Jiang W, Lu B, Kalinski P, Guo Z Mol Cancer. 2022; 21(1):196.

PMID: 36221123 PMC: 9554963. DOI: 10.1186/s12943-022-01664-z.

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics.

McCloskey C, Rodriguez G, Galpin K, Vanderhyden B Cancers (Basel). 2018; 10(8).

PMID: 30049987 PMC: 6115831. DOI: 10.3390/cancers10080244.

Tumor Restrictions to Oncolytic Virus.

Vaha-Koskela M, Hinkkanen A Biomedicines. 2017; 2(2):163-194.

PMID: 28548066 PMC: 5423468. DOI: 10.3390/biomedicines2020163.

References

Bannister A, Kouzarides T . Regulation of chromatin by histone modifications. Cell Res. 2011; 21(3):381-95. PMC: 3193420. DOI: 10.1038/cr.2011.22. View

Londhe P, Zhu B, Abraham J, Keller C, Davie J . CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells. Int J Cancer. 2011; 131(4):E437-48. PMC: 3271171. DOI: 10.1002/ijc.26478. View

Galanis E, Markovic S, Suman V, Nuovo G, Vile R, Kottke T . Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther. 2012; 20(10):1998-2003. PMC: 3464629. DOI: 10.1038/mt.2012.146. View

Kanaseki T, Ikeda H, Takamura Y, Toyota M, Hirohashi Y, Tokino T . Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. J Immunol. 2003; 170(10):4980-5. DOI: 10.4049/jimmunol.170.10.4980. View

Maldonado A, Klanke C, Jegga A, Aronow B, Mahller Y, Cripe T . Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors. J Gene Med. 2010; 12(7):613-23. DOI: 10.1002/jgm.1479. View

Satoh A, Toyota M, Ikeda H, Morimoto Y, Akino K, Mita H . Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene. 2004; 23(55):8876-86. DOI: 10.1038/sj.onc.1208144. View

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

Muntean A, Hess J . Epigenetic dysregulation in cancer. Am J Pathol. 2009; 175(4):1353-61. PMC: 2751531. DOI: 10.2353/ajpath.2009.081142. View

Russell S, Peng K, Bell J . Oncolytic virotherapy. Nat Biotechnol. 2012; 30(7):658-70. PMC: 3888062. DOI: 10.1038/nbt.2287. View

10.

Muhlethaler-Mottet A, Di Berardino W, Otten L, MACH B . Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity. 1998; 8(2):157-66. DOI: 10.1016/s1074-7613(00)80468-9. View

11.

Cedar H, Bergman Y . Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009; 10(5):295-304. DOI: 10.1038/nrg2540. View

12.

Vigneau S, Levillayer F, Crespeau H, Cattolico L, Caudron B, Bihl F . Homology between a 173-kb region from mouse chromosome 10, telomeric to the Ifng locus, and human chromosome 12q15. Genomics. 2001; 78(3):206-13. DOI: 10.1006/geno.2001.6656. View

13.

Suh H, Choi S, Khattar P, Choi N, Lee S . Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes. J Neuroimmune Pharmacol. 2010; 5(4):521-32. PMC: 3115474. DOI: 10.1007/s11481-010-9192-0. View

14.

Setiadi A, David M, Seipp R, Hartikainen J, Gopaul R, Jefferies W . Epigenetic control of the immune escape mechanisms in malignant carcinomas. Mol Cell Biol. 2007; 27(22):7886-94. PMC: 2169144. DOI: 10.1128/MCB.01547-07. View

15.

Magnani L, Eeckhoute J, Lupien M . Pioneer factors: directing transcriptional regulators within the chromatin environment. Trends Genet. 2011; 27(11):465-74. DOI: 10.1016/j.tig.2011.07.002. View

16.

Johnsen A, Templeton D, Sy M, Harding C . Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol. 1999; 163(8):4224-31. View

17.

Farassati F, Yang A, Lee P . Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol. 2001; 3(8):745-50. DOI: 10.1038/35087061. View

18.

Borden E . Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma. Cytokine Growth Factor Rev. 2007; 18(5-6):491-501. PMC: 2682546. DOI: 10.1016/j.cytogfr.2007.06.022. View

19.

Janson P, Marits P, Thorn M, Ohlsson R, Winqvist O . CpG methylation of the IFNG gene as a mechanism to induce immunosuppression [correction of immunosupression] in tumor-infiltrating lymphocytes. J Immunol. 2008; 181(4):2878-86. DOI: 10.4049/jimmunol.181.4.2878. View

20.

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View